The investment is set to create 725 new jobs in Ireland over the next ten years.
The new jobs will be across R&D manufacturing, science and engineering located in its Parkmore, Galway and Shannon sites.
This development will increase Aerogen's global workforce to over 2,000 with 1,100 employees based in Ireland. It will also build its emerging biopharmaceutics business with a major breakthrough in treating premature new-borns with Infant Respiratory Stress Syndrome.
The expansion will help the company accelerate its existing device technology through new product innovations
Aerogen is Ireland's largest indigenous medtech company and is known for its acute care aerosol drug delivery.
The drugs created by the company help to treat critical respiratory illnesses and other non-respiratory illnesses.
The announcement coincides with Enterprise Ireland's End of Year Results 2024 which shows the total employment of companies supported by Enterprise Ireland increased to 234,454 last year, with 15,741 new jobs created.
Minister for Enterprise, Trade and Employment Peter Burke was on site in Galway to preside over Aerogen’s growth announcement and deliver Enterprise Ireland’s results. “The government through Enterprise Ireland is targeting ambitious scaling of Irish multinationals that will help drive the Irish economy and our competitive advantage forward. Aerogen’s announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission.
